Pomerantz Law Firm has launched an investigation into potential securities violations at Pharming Group N.V. following the U.S. Food and Drug Administration's issuance of a Complete Response Letter that rejected the company's supplemental application for Joenja® (leniolisib) in pediatric patients. The regulatory setback prompted a significant market reaction, with the company's stock declining 17.07% on February 2, 2026.
The FDA's rejection cited two primary concerns regarding the drug application: insufficient efficacy data in lower weight pediatric patients, indicating potential drug underexposure in this population, and unresolved issues related to the analytical methods used in testing. These deficiencies prevented the agency from approving the expanded indication at this time, requiring the company to address the identified gaps before resubmission.
The investigation examines whether Pharming Group's disclosures to investors adequately reflected the regulatory risks associated with the pediatric application. Securities litigation of this nature typically focuses on whether material information regarding product development challenges was appropriately communicated during the period preceding the FDA decision. The law firm is accepting inquiries from investors who sustained losses during the relevant timeframe.